Post by marriott on Feb 25, 2023 19:27:01 GMT
The coming conference call will stand out because we will hear directly from John C. Jacobs , President & Chief Executive Officer .
We have been advised that Mr Jacobs will bring “ more than 25 years of commercial, operations, business and leadership experience across multiple therapeutic areas “ to Novavax going forward .
Obviously, earnings results will be discussed . It will be interesting to hear the real world REASONS behind the results . Berating past management at this time is , in my opinion , like throwing the baseball to first base when the runner is on his way to third.
Current leadership needs to detail a product manufacturing structure layout with the different process steps from planning to packaging of the vaccines and delivery to the markets . And, talk about where that market is today !
Then , how will the company present future outlook regarding sales, forecasts, product development , growth opportunities …..etc.
It will be very interesting if the patent expiration for Matrix-M is brought to light . Specifically , it is covered by patent #10544399 and is scheduled to expire on July 11, 2023.
For those of us who are mentally befuddled , how about a clear and concise business strategy going forward .